Recent News

• 11.05.2026 - Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
• 11.05.2026 - Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
• 11.04.2026 - Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
• 11.02.2026 - Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
• 10.29.2026 - Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
• 10.14.2026 - Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
• 09.28.2026 - Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
• 08.27.2026 - Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
• 08.13.2026 - Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
• 08.05.2026 - Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001

Recent Filings

• 11.05.2026 - 8-K Current report
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 11.05.2026 - EX-99.1 EX-99.1
• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.02.2026 - 8-K Current report
• 11.02.2026 - EX-99.1 EX-99.1
• 10.14.2026 - 8-K Current report
• 10.14.2026 - EX-99.1 EX-99.1
• 10.06.2026 - 4 Statement of changes in beneficial ownership of securities